SAN RAFAEL, Calif. - Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a pioneer in exoskeleton technology, announced today that the Centers for Medicare & Medicaid Services (CMS) has processed claims and issued payment for its Ekso Indego Personal exoskeleton. The reimbursement, based on the established $91,032 rate under HCPCS code K1007 effective April 1, 2024, marks a significant milestone for the company and Medicare beneficiaries with spinal cord injuries (SCI).
Scott Davis, CEO of Ekso Bionics, expressed the company's excitement over the initial CMS reimbursement, highlighting the device's potential to enhance mobility and independence for individuals with SCI. The Ekso Indego Personal is designed to be lightweight and modular, allowing users to don and remove the device without assistance. It also features an advanced gait mode to enable faster walking speeds.
The company has launched the EksoHealth Personal Program in the U.S. to assist patients in accessing these personal exoskeletons. The program includes a screening process to ensure candidates are suitable for the device and offers training with certified therapists for home and community use.
Ekso Bionics plans to work with Medicare Advantage plans and commercial insurers later in 2024, aiming to tap into a broader market of tens of thousands of individuals covered by Medicare. The company's engagement with partner rehabilitation centers is growing as they prepare to meet the anticipated demand.
Debbie Wagoner, the first individual to acquire an Ekso Indego Personal through CMS, shared her positive experience with the device, emphasizing the significant impact on her rehabilitation journey. The company's goal is to make the exoskeletons more accessible to those in need.
Ekso Bionics, headquartered in the San Francisco Bay Area, has been at the forefront of developing wearable robotic exoskeletons for both medical and industrial applications since 2005. The company's products are designed to support and enhance human strength, endurance, and mobility.
The information for this article is based on a press release statement from Ekso Bionics Holdings, Inc.
In other recent news, Ekso Bionics Holdings, Inc. reported record-breaking quarterly sales of $5 million in the second quarter of 2024. The company also sold 37 EksoHealth devices and received a favorable payment decision from the Centers for Medicare & Medicaid Services (CMS) for their Ekso Indego Personal device. Despite a slight revenue decrease in the first half of 2024, Ekso Bionics managed to reduce operating expenses and is focusing on market expansion and improving access to its exoskeleton devices.
Furthermore, the company anticipates the Indego Personal program to significantly impact revenue from 2025 onwards. In addition, Ekso Bionics is expanding access to their exoskeleton devices and targeting a larger market share. The company is also building a scalable process to reach more individuals with spinal cord injuries.
However, the first half of 2024 saw a slight decrease in revenue compared to the same period in the previous year. Despite record quarterly sales, the company reported a net loss of $5.8 million for the first half of 2024. These are among the recent developments concerning Ekso Bionics.
InvestingPro Insights
As Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) makes strides in the healthcare sector with the reimbursement for its Ekso Indego Personal exoskeleton, the financial health of the company remains a focal point for investors. According to InvestingPro data, Ekso Bionics currently holds a market capitalization of $16.23 million, reflecting the company's valuation in the market. Despite recent challenges, analysts are optimistic about the company's future, predicting a return to profitability this year. This outlook is supported by a revenue growth of 15.63% over the last twelve months as of Q2 2024, indicating a positive trajectory in the company's sales performance.
InvestingPro Tips suggest that while Ekso's stock has experienced significant volatility and a notable decline over the past six months, with a 53.68% drop in price total return, the company's liquid assets surpass its short-term obligations, providing a cushion against immediate financial pressures. Additionally, with a gross profit margin of 51.83%, Ekso demonstrates a strong ability to retain earnings over its revenue, which could be a promising sign for potential investors.
Investors looking for further insights into Ekso Bionics' performance metrics and future projections can find an additional 10 InvestingPro Tips on the InvestingPro platform, providing a comprehensive analysis of the company's financial health and stock performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.